Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
The first clinical trial is expected to commence in early 2022 both in Europe and the US
Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
Ibuprofen and Famotidine tablets (Duexise) had estimated annual sales of US $ 765 million in the US as if July 21
Research collaboration covers multiple antibody research programs
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The clinical research organisation located in Hyderabad is a USFDA inspected facility
Subscribe To Our Newsletter & Stay Updated
